缬沙坦对心房颤动患者基质金属蛋白酶-2及其抑制因子的影响  

Effects of valsartan on matrix metalloproteinase-2 and its inhibitor in atrial fibrillation patients

作　　者：胡雪松[1] 潘莹[2] 张国良[1] 裴晓阳[1] 张新霞[1] 

机构地区：[1]广东医学院附属深圳市福田人民医院心内科,深圳518026 [2]深圳市龙岗区人民医院心内科,广东深圳518033

出　　处：《岭南心血管病杂志》2008年第6期404-407,共4页South China Journal of Cardiovascular Diseases

摘　　要：目的观察缬沙坦对非瓣膜性心房颤动(non-vavular atrial fibrillation,NVAF)患者血清基质金属蛋白酶-2(matrix metalloproteinases2,MMP2)与组织金属蛋白酶抑制因子-2(tissue inhibitor of metalloproteinase,TIMP2)的影响,探讨其延缓或阻滞心房颤动进程的可能机制。方法心房颤动组27例,属NVAF。再分为缬沙坦组13例,每日口服缬沙坦80mg;对照组14例,不服用任何血管紧张素转化酶抑制药和血管紧张素Ⅱ受体阻断药。窦律组为同期入院呈窦性心律人群26例。采用酶联免疫吸附试验测定各组治疗前及治疗3个月后血清MMP2和TIMP2,记录心房颤动的复发率。结果心房颤动组血清MMP2明显高于窦律组;血清TIMP2较窦律组低。治疗3个月后,缬沙坦组血清MMP2较治疗前以及对照组降低;而血清TIMP2较治疗前水平增加。血清MMP2与左心房直径呈正相关。结论NVAF患者血清MMP2水平较高,缬沙坦组可降低血清中MMP2,升高血清TIMP2,提示缬沙坦可能通过改变MMP2和TIMP2参与心房重构。Objectives To study the effect of valsartan on the plasma matrix metalloproteinase-2(MMP2) and tissue inhibitor of matrix metalloproteinase-2(TIMP2) in patients with non-vavular atrial fibrillation(NVAF) and to investigate its possible mechanism.Methods Twenty-seven patients with NVAF were divided into valsartan group which included 13 patients given valsartan 80 mg a day,control group which included 14 patients,while sinus group,including twenty-six patients with sinus rhythm.Plasma MMP2 and TIMP2 levels w...

关 键 词：心房颤动 缬沙坦 基质金属蛋白酶 肾素-血管紧张素系统 心房重构 

分 类 号：R541.75[医药卫生—心血管疾病]